{"url_path":"/sec/nrxpw/8-k/2026-06-04/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1719406/0001437749-26-019576-index.html","accession_number":"0001437749-26-019576","cik":"0001719406","ticker":"NRXP","issuer_name":"NRX Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1719406/0001437749-26-019576-index.html","primary_entity_key":"0001719406","primary_entity_name":"NRX Pharmaceuticals, Inc."},"word_count":127,"has_tables":true,"body_markdown":"**Item 9.01.**\n\n**Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits:\n\n \n\n**Exhibit No.**\n\n \n\n**Description**\n\n \n \n \n\n1.1\n\n \n\n[Underwriting Agreement dated June 3, 2026, by and between NRx Pharmaceuticals, Inc. and BTIG, LLC, as representative of the several underwriters named therein.](ex_972120.htm)\n\n \n \n \n\n5.1\n\n \n\n[Legal Opinion of Cozen O’Connor.](ex_972121.htm)\n\n \n \n \n\n23.1\n\n \n\n[Consent of Cozen O’Connor (included in Exhibit 5.1).](ex_972121.htm)\n\n \n \n \n\n99.1\n\n \n\n[Press Release dated June 3, 2026.](ex_972122.htm)\n\n \n \n \n\n99.2\n\n \n\n[Press Release dated June 4, 2026.](ex_972572.htm)\n\n \n \n \n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n**NRX PHARMACEUTICALS, INC.**\n\n \n\n \n \n \n\nDate: June 4, 2026\n\nBy:\n\n*/s/ Jonathan Javitt*\n\n \n\n \n\nName:\n\nJonathan Javitt\n\n \n\n \n\nTitle:\n\nChief Executive Officer"}